Physician profile
Anna K Erwin
NPI 1710249271
$3,752.31
in general payments reported to CMS, 2019-2025
25 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,150 · 2022: $960 · 2023: $705 · 2024: $598 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,034.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $900.20 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $330.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.95 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $221.62 | 2021-2022 | |
| Pfizer INC. | $200.75 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $133.18 | 2021-2022 | |
| Lilly USA, LLC | $60.54 | 2021-2024 | Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $57.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.15 | 2021-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $53.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $53.39 | 2021 | |
| Halozyme INC | $49.78 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $45.73 | 2023 | Seglentis |
| Otsuka America Pharmaceutical, INC. | $38.90 | 2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $31.74 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $27.81 | 2021-2022 | |
| Lundbeck LLC | $20.53 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $18.29 | 2024 | Xarelto |
| Amarin Pharma, INC. | $18.04 | 2021 | |
| Metacel Pharmaceuticals LLC | $15.50 | 2023 | Ozobax |
| Amgen INC. | $14.99 | 2021 | |
| Mylan Specialty L.P. | $14.86 | 2021 | |
| Biogen, INC. | $13.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Erwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.